Literature DB >> 8093825

T-cells and psychopathology in schizophrenia: relationship to the outcome of neuroleptic therapy.

N Müller1, E Hofschuster, M Ackenheil, R Eckstein.   

Abstract

Until recently, attention has been focused on the pathogenetic aspects of immunological findings in schizophrenic patients. There has been no mention of the relationship between such findings and schizophrenic symptoms. To study the probable relationship between T-cells and T-cell subgroups in the course and prognosis of schizophrenia, immunological and psychopathological parameters were correlated in 55 patients suffering from schizophrenia (ICD-9: 295.0-295.6) or schizoaffective psychosis (ICD-9: 257.7) before neuroleptic treatment. The correlations were performed for a second time in 24 of these patients after clinical improvement at a reinvestigation. Positive correlations of the Brief Psychiatric Rating Scale and the Scale for Assessment of Negative Symptoms with the numbers of CD3+ and CD4+ T-cells (total T- and T-helper cells), which were enhanced compared with controls, were found at the reinvestigation after clinical improvement, whereas no significant correlation could be detected at the pretreatment investigation. These results show that the cellular immune parameters are related to the course of the psychopathological symptoms in schizophrenia and, possibly, are a marker of the therapeutic outcome or neuroleptic treatment.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8093825     DOI: 10.1111/j.1600-0447.1993.tb03331.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  10 in total

1.  Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients.

Authors:  I Wilke; V Arolt; M Rothermundt; C Weitzsch; M Hornberg; H Kirchner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1996       Impact factor: 5.270

2.  The effects of Ginkgo biloba extract added to haloperidol on peripheral T cell subsets in drug-free schizophrenia: a double-blind, placebo-controlled trial.

Authors:  Xiang Yang Zhang; Dong Feng Zhou; Lian Yuan Cao; Gui Ying Wu
Journal:  Psychopharmacology (Berl)       Date:  2006-08-12       Impact factor: 4.530

Review 3.  Adaptive Immunity in Schizophrenia: Functional Implications of T Cells in the Etiology, Course and Treatment.

Authors:  Monojit Debnath
Journal:  J Neuroimmune Pharmacol       Date:  2015-07-11       Impact factor: 4.147

4.  Meta-analysis of lymphocytes in schizophrenia: clinical status and antipsychotic effects.

Authors:  Brian J Miller; Bintou Gassama; Dale Sebastian; Peter Buckley; Andrew Mellor
Journal:  Biol Psychiatry       Date:  2012-10-11       Impact factor: 13.382

5.  Lower serum cytokine levels in smokers than nonsmokers with chronic schizophrenia on long-term treatment with antipsychotics.

Authors:  Xiang Yang Zhang; Lian Yuan Cao; Cai Song; Gui Ying Wu; Da Chun Chen; Ling Yan Qi; Fan Wang; Mei Hong Xiu; Song Chen; Yingyang Zhang; Lin Lu; Therese A Kosten; Thomas R Kosten
Journal:  Psychopharmacology (Berl)       Date:  2008-08-22       Impact factor: 4.530

6.  Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression.

Authors:  M Maes; H Y Meltzer; P Buckley; E Bosmans
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1995       Impact factor: 5.270

7.  Treatment with the antipsychotic agent, risperidone, reduces disease severity in experimental autoimmune encephalomyelitis.

Authors:  David O'Sullivan; Laura Green; Sarrabeth Stone; Pirooz Zareie; Marie Kharkrang; Dahna Fong; Bronwen Connor; Anne Camille La Flamme
Journal:  PLoS One       Date:  2014-08-12       Impact factor: 3.240

Review 8.  Therapeutic Drug Monitoring of Second- and Third-Generation Antipsychotic Drugs-Influence of Smoking Behavior and Inflammation on Pharmacokinetics.

Authors:  Nicole Moschny; Gudrun Hefner; Renate Grohmann; Gabriel Eckermann; Hannah B Maier; Johanna Seifert; Johannes Heck; Flverly Francis; Stefan Bleich; Sermin Toto; Catharina Meissner
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-27

9.  Increased serum interleukin-1beta and interleukin-6 in elderly, chronic schizophrenic patients on stable antipsychotic medication.

Authors:  Andrea Schmitt; Thomas Bertsch; Heike Tost; Andrea Bergmann; Uwe Henning; Ansgar Klimke; Peter Falkai
Journal:  Neuropsychiatr Dis Treat       Date:  2005-06       Impact factor: 2.570

10.  The Microbiome: A New Target for Research and Treatment of Schizophrenia and its Resistant Presentations? A Systematic Literature Search and Review.

Authors:  Alessandro Cuomo; Giuseppe Maina; Gianluca Rosso; Bruno Beccarini Crescenzi; Simone Bolognesi; Angela Di Muro; Nicola Giordano; Arianna Goracci; Stephen M Neal; Maria Nitti; Fulvio Pieraccini; Andrea Fagiolini
Journal:  Front Pharmacol       Date:  2018-10-15       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.